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The toolkit on disinvestment 
A jointly effort  performed by HTAi IG on DEA, IG 
on ethics, EuroScan network and INAHTA is aiming 
to elaborate a toolkit that could aid organizations 
and individuals on the steps to be developed 
when considering disinvestment activities.  
This presentation refers to one of the chapters of 
that book on identification activities and 
disinvestment.  
Introduction 
Health technology has no or low added value 
when it is harmful and/or is deemed to deliver 
limited health gain relative to its cost, 
representing inefficient health resource 
allocation*. 
 
 
Adam Elshaug 
Introduction (I) 
• Here, we synthesized 
state of the art methods 
for identifying candidate 
technologies for 
disinvestment, and 
propose a framework 
for executing this task. 
 
 
Introduction (II) 
• The traditional linear concept of health 
technologies life cycle  assumes that 
once decisions on reimbursement 
were taken, health technologies 
remained unassessed up to their 
disuse by health professionals:  under 
this conception, technologies follow a 
linear path, involving sequential steps 
from inception to obsolescence. 
• The life cycle of a technology is multi-
faceted and multi-dimensional, 
depending on the nature and number 
of uses 
Methods 
We searched systematic reviews on disinvestment 
and compared the methods used for identifying 
potential candidates.  
A descriptive analysis was performed including 
sources of evidence used and methods for 
selection / filtration. 
 
Ten reviews on disinvestment initiatives worldwide 
were identified.  
One of them was specifically focused on 
methodologies for identifying and prioritizing 
candidate technologies for disinvestment (REDETS, 
Lain Entralgo, 2012) 
Results 
Results 
Elshaug A. et al 2009.  
 
The framework consisted in twelve items 
(“triggers”) (Table 1), Application of these 
triggers through “horizon scanning” 
techniques facilitated the systematic and 
transparent identification of existing 
potentially ineffective technologies and 
medical practices.  
Results 
• Gallego G et al, 2010. 
authors proposed other 
strategies by which 
appraisal of existing 
technologies might be 
triggered like the 
comparative effectiveness 
research, research into 
clinical practice variations 
and Program Budget and 
Marginal Analysis (PBMA) 
Results 
• Ludwig Boltzman 
Institute, 2011. Describe 
that there were 
consensus on the 
methods of 
identification and 
prioritisation but not 
methodological 
guidelines   
Results 
• Health Technology Assessment 
International (HTAi) Policy 
Forum met in San Francisco, 
USA, 2012 to explore the use 
and role of HTA in the 
reduction of lower value or 
ineffective uses of Health 
Technology.  
• Members of the Forum 
proposed different approaches 
for the identification of 
technologies for reassessment 
Basic approaches for 
identification 
• “Context-free scientific evidence driven 
approach”  (Approach 1) provided by systematic 
reviews, evidence-based clinical practice 
guidelines, effectiveness and safety assessment 
included in HTA reports.   
• “Context-sensitive scientific evidence driven 
approach” (Approach 2): analysis of the 
implementation, organizational capacity, 
economics, legal and ethical issues related to the 
use of an specific technology in an certain 
context. PBMA or cost-effectiveness analysis.  
• “Colloquial evidence driven approach” 
(Approach 3): evidence that comes from the 
expertise, views and realities of stakeholders.   
• “Combined-evidence driven approaches” 
(Approach 4, 5, 6 and 7): four different options, 
depending on the amount and types of evidence 
that are combined. 
Triggers for identifying 
candidates (I) 
• Triggers based on context-
sensitive scientific evidence 
– Geographic variations in 
care 
– Provider variations in care  
– Practice inconsistency with 
evidence-based standards 
– Temporal variations in 
volume 
– Leakage 
 
• Triggers based on context-free 
scientific evidence 
– Evidence on 
Ineffectiveness/Patient 
Safety concerns/Inefficiency 
– Displacement of an old 
intervention by a new one 
– Uncertainties related to 
“Legacy” technologies 
– Uncertainties related to 
“newer/extended uses” of a 
technologies 
 
Triggers for identifying 
candidates (III) 
• Triggers based on colloquial 
evidence 
– Negative experiences or 
perceptions from 
community members 
– Negative experiences or 
perceptions from health 
system workers, 
administrators and/or 
funders 
 
 
Methods for identifying candidate 
technologies for disinvestment 
• Ad Hoc Methods 
– Horizon or Environmental Scanning 
– Identification of opportunities for 
disinvestment from evidence-based 
guidelines and/or HTA reports 
– Identification of potential candidates for 
disinvestment from systematic reviews 
(SR) 
– Adaptation of existing list of no-value 
technologies 
– Comparative Effectiveness Research 
(CER) 
– Research into clinical variation practices 
– Program Budgeting and Marginal 
Analysis (PBMA) 
– Nomination and consultation methods 
 
• Embedded methodologies 
– Horizon Scanning of existing 
technologies 
– Inclusion of triggers for identifying 
candidate technologies for 
disinvestment in purchasing and 
procurement processes 
– Inclusion of triggers for identifying 
candidate technologies for 
disinvestment in the guideline 
development process 
– Inclusion of triggers for identifying 
candidate technologies for 
disinvestment in system redesign 
processes related to resource 
allocation 
– Routine use of local data 
 
Final remarks 
Conclusions 
• There was overlapping among the terms used for describing the different 
approaches. 
• Our proposal differentiating basic approaches, triggers for identifying potential 
technologies and methods that can be used. 
• Scientific and/or colloquial evidence should guide the identification of 
opportunities for disinvestment.  
• Context-free scientific evidence allows the identification of ineffective and/or 
harmful technologies on the basis of valid and reliable methods.  
• Needs to be contextualized. Context-sensitive scientific evidence establishes, 
which technology or practice is relevant in a certain area or institution due to 
its variability, burden and/or budget impact. 
• Stakeholders involvement is crucial, at least for legitimacy and acceptability 
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